NASDAQ · BMRA
Healthcare · Medical - Devices
$2.39
Down-$0.06 (-2.72%)
Updated Sep 29, 2026, 4:27 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BMRA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 28, 2026
BMRA closed at $2.39 after 20 trading sessions, up 14.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 28, 2026 | $2.30 | $2.3899 | $2.2868 | $2.3899 | 7.14K |
| Sep 25, 2026 | $2.43 | $2.64 | $2.18 | $2.32 | 58.58K |
| Sep 24, 2026 | $2.60 | $2.64 | $2.44 | $2.46 | 50.98K |
| Sep 23, 2026 | $2.79 | $2.84 | $2.58 | $2.605 | 37.58K |
| Sep 22, 2026 | $2.60 | $2.78 | $2.57 | $2.78 | 42.05K |
| Sep 21, 2026 | $2.55 | $2.60 | $2.4101 | $2.60 | 23.07K |
| Sep 18, 2026 | $2.335 | $2.52 | $2.30 | $2.51 | 75.83K |
| Sep 17, 2026 | $2.305 | $2.4099 | $2.26 | $2.36 | 37.66K |
| Sep 16, 2026 | $2.27 | $2.42 | $2.27 | $2.37 | 13.68K |
| Sep 15, 2026 | $2.36 | $2.39 | $2.28 | $2.30 | 17.5K |
| Sep 14, 2026 | $2.26 | $2.41 | $2.18 | $2.36 | 28.22K |
| Sep 11, 2026 | $2.25 | $2.29 | $2.13 | $2.24 | 11.94K |
| Sep 10, 2026 | $2.1701 | $2.2456 | $2.1701 | $2.23 | 15.37K |
| Sep 9, 2026 | $2.35 | $2.35 | $1.97 | $2.265 | 21.41K |
| Sep 8, 2026 | $2.27 | $2.3799 | $2.205 | $2.34 | 85.27K |
| Sep 4, 2026 | $2.27 | $2.35 | $2.21 | $2.31 | 54.6K |
| Sep 3, 2026 | $2.21 | $2.3305 | $2.17 | $2.22 | 58.9K |
| Sep 2, 2026 | $2.05 | $2.20 | $1.9806 | $2.20 | 72.82K |
| Sep 1, 2026 | $2.11 | $2.15 | $1.94 | $2.09 | 34.37K |
| Aug 31, 2026 | $2.15 | $2.16 | $2.01 | $2.09 | 51.13K |
The latest Smart Investors Daily articles mentioning BMRA.
BMRA research
Company profile and research snapshot.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2020 | Aegis Capital | Buy | — |
| Sep 4, 2020 | Aegis Capital | Buy | — |
| Aug 21, 2020 | Aegis Capital | Buy | — |
| Dec 17, 2018 | B. Riley FBR | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 24, 2026
BIOMERICA, INC. 1,403,705 Shares of Common Stock This prospectus relates to the proposed resale or other disposition by the selling stockholders identified in this prospectus of up to 1,403,705 shares of our common
Yahoo · Sep 1, 2026
Fiscal 2026 fourth quarter net sales increased approximately 17% compared to the fourth quarter of fiscal 2025Full-year net loss improved by approximately 24% to approximately $3.8 millionInFoods IBS update: 100% of all initial valid claims processed to date have been paid at the full CMS payment rate of $300Research and development expenses decreased 23% as key programs transition toward commercializationSubsequent to fiscal year-end: completed a $2.23 million financing with no warrants or disc
Benzinga · Sep 1, 2026
Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.38) per share. This is a 44.93 percent increase over losses of $(0.69) per share from the same period last year. The company reported $875.000 thousand in sales
Benzinga · Aug 28, 2026
Major M&A deals this week include: The Descartes Systems buys Tai, KKR nabs Ci FLAVORS, Skimmer Acquires Pool Builder Geek and Poologics.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BMRA.
